Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A single flow cytometric MRD measurement in children with B-lineage acute lymphocytic leukemia and hyperleukocytosis redefines the requirements of high-risk treatment: Results of the study ALL-MB 2008.
Popov A, Henze G, Roumiantseva J, Budanov O, Belevtsev M, Verzhbitskaya T, Boyakova E, Movchan L, Tsaur G, Fadeeva M, Lagoyko S, Zharikova L, Miakova N, Litvinov D, Khlebnikova O, Streneva O, Stolyarova E, Ponomareva N, Novichkova G, Fechina L, Aleinikova O, Karachunskiy A. Popov A, et al. Among authors: roumiantseva j. Leuk Res. 2022 Dec;123:106982. doi: 10.1016/j.leukres.2022.106982. Epub 2022 Oct 22. Leuk Res. 2022. PMID: 36332292 No abstract available.
Results of the first randomized multicentre trial on childhood acute lymphoblastic leukaemia in Russia.
Karachunskiy A, Herold R, von Stackelberg A, Miakova N, Timakow A, Mahortih T, Bajdun L, Maschan A, Fechina L, Shamardina A, Dudkin S, Lebedev V, Varfolomeeva S, Timofeeva V, Roumiantseva J, Chipsanova N, Rumjanzew A, Henze G. Karachunskiy A, et al. Among authors: roumiantseva j. Leukemia. 2008 Jun;22(6):1144-53. doi: 10.1038/leu.2008.63. Epub 2008 Mar 27. Leukemia. 2008. PMID: 18368070 Clinical Trial.
Therapy of advanced-stage mature B-cell lymphoma and leukemia in children and adolescents with rituximab and reduced intensity induction chemotherapy (B-NHL 2004M protocol): the results of a multicenter study.
Samochatova EV, Maschan AA, Shelikhova LN, Myakova NV, Belogurova MB, Khlebnikova OP, Shamardina AV, Ryskal OV, Roumiantseva JV, Konovalov DM, Dubrovina ME, Rumyantsev AG. Samochatova EV, et al. J Pediatr Hematol Oncol. 2014 Jul;36(5):395-401. doi: 10.1097/MPH.0b013e31829d4900. J Pediatr Hematol Oncol. 2014. PMID: 23823112
Efficacy and toxicity of dexamethasone vs methylprednisolone-long-term results in more than 1000 patients from the Russian randomized multicentric trial ALL-MB 2002.
Karachunskiy A, Roumiantseva J, Lagoiko S, Bührer C, Tallen G, Aleinikova O, Bydanov O, Korepanova N, Bajdun L, Nasedkina T, von Stackelberg A, Novichkova G, Maschan A, Litvinov D, Myakova N, Ponomareva N, Kondratchik K, Fechina L, Streneva O, Judina N, Scharapova G, Shamardina A, Gerbek I, Shapochnik A, Rumjanzew A, Henze G; ALL-MB study group. Karachunskiy A, et al. Among authors: roumiantseva j. Leukemia. 2015 Sep;29(9):1955-8. doi: 10.1038/leu.2015.63. Epub 2015 Mar 9. Leukemia. 2015. PMID: 25748686 No abstract available.
Absolute count of leukemic blasts in cerebrospinal fluid as detected by flow cytometry is a relevant prognostic factor in children with acute lymphoblastic leukemia.
Popov A, Henze G, Verzhbitskaya T, Roumiantseva J, Lagoyko S, Khlebnikova O, Streneva O, Bidanov O, Tsaur G, Inaba H, Karachunskiy A, Fechina L. Popov A, et al. Among authors: roumiantseva j. J Cancer Res Clin Oncol. 2019 May;145(5):1331-1339. doi: 10.1007/s00432-019-02886-3. Epub 2019 Mar 6. J Cancer Res Clin Oncol. 2019. PMID: 30840196
Reduced vs. standard dose native E. coli-asparaginase therapy in childhood acute lymphoblastic leukemia: long-term results of the randomized trial Moscow-Berlin 2002.
Karachunskiy A, Tallen G, Roumiantseva J, Lagoiko S, Chervova A, von Stackelberg A, Aleinikova O, Bydanov O, Bajdun L, Nasedkina T, Korepanova N, Kuznetsov S, Novichkova G, Goroshkova M, Litvinov D, Myakova N, Ponomareva N, Inyushkina E, Kondratchik K, Abugova J, Fechina L, Arakaev O, Karelin A, Lebedev V, Judina N, Scharapova G, Spichak I, Shamardina A, Ryskal O, Shapochnik A, Rumjanzew A, Boos J, Henze G; ALL-MB study group. Karachunskiy A, et al. Among authors: roumiantseva j. J Cancer Res Clin Oncol. 2019 Apr;145(4):1001-1012. doi: 10.1007/s00432-019-02854-x. Epub 2019 Mar 6. J Cancer Res Clin Oncol. 2019. PMID: 30840197 Free PMC article. Clinical Trial.
Strong expansion of normal CD19-negative B-cell precursors after the use of blinatumomab in the first-line therapy of acute lymphoblastic leukaemia in children.
Mikhailova E, Roumiantseva J, Illarionova O, Lagoyko S, Miakova N, Zerkalenkova E, Zharikova L, Olshanskaya Y, Novichkova G, Maschan M, Henze G, Karachunskiy A, Popov A. Mikhailova E, et al. Among authors: roumiantseva j. Br J Haematol. 2022 Jan;196(1):e6-e9. doi: 10.1111/bjh.17760. Epub 2021 Aug 3. Br J Haematol. 2022. PMID: 34346071 No abstract available.
A simple algorithm with one flow cytometric MRD measurement identifies more than 40% of children with ALL who can be cured with low-intensity therapy. The ALL-MB 2008 trial results.
Popov A, Henze G, Roumiantseva J, Budanov O, Belevtsev M, Verzhbitskaya T, Boyakova E, Movchan L, Tsaur G, Fadeeva M, Lagoyko S, Zharikova L, Miakova N, Litvinov D, Khlebnikova O, Streneva O, Stolyarova E, Ponomareva N, Novichkova G, Fechina L, Aleinikova O, Karachunskiy A. Popov A, et al. Among authors: roumiantseva j. Leukemia. 2022 May;36(5):1382-1385. doi: 10.1038/s41375-022-01542-z. Epub 2022 Mar 23. Leukemia. 2022. PMID: 35322171 No abstract available.
B-lineage antigens that are useful to substitute CD19 for minimal residual disease monitoring in B cell precursor acute lymphoblastic leukemia after CD19 targeting.
Mikhailova E, Itov A, Zerkalenkova E, Roumiantseva J, Olshanskaya Y, Karachunskiy A, Novichkova G, Maschan M, Popov A. Mikhailova E, et al. Among authors: roumiantseva j. Cytometry B Clin Cytom. 2022 Sep;102(5):353-359. doi: 10.1002/cyto.b.22088. Epub 2022 Jul 7. Cytometry B Clin Cytom. 2022. PMID: 35796438 Free article.
One-point flow cytometric MRD measurement to identify children with excellent outcome after intermediate-risk BCP-ALL: results of the ALL-MB 2008 study.
Popov A, Henze G, Roumiantseva J, Budanov O, Belevtsev M, Verzhbitskaya T, Boyakova E, Movchan L, Tsaur G, Fadeeva M, Lagoyko S, Zharikova L, Miakova N, Litvinov D, Khlebnikova O, Streneva O, Stolyarova E, Ponomareva N, Novichkova G, Fechina L, Aleinikova O, Karachunskiy A. Popov A, et al. Among authors: roumiantseva j. J Cancer Res Clin Oncol. 2023 Jul;149(8):4629-4637. doi: 10.1007/s00432-022-04378-3. Epub 2022 Sep 28. J Cancer Res Clin Oncol. 2023. PMID: 36169717
15 results